RATIONALE: Bronchiolitis obliterans syndrome (BOS), defined by loss of lung function, develops in the majority of lung transplant recipients. However, there is a paucity of information on the subsequent course of lung function in these patients. OBJECTIVES: To characterize the course of FEV(1) over time after development of BOS and to determine the predictors that influence the rate of functional decline of FEV(1). METHODS: FEV(1)% predicted (FEV(1)%pred) trajectories were studied in 111 lung transplant recipients with BOS by multivariate, linear, mixed-effects statistical models. MEASUREMENTS AND MAIN RESULTS: FEV(1)%pred varied over time after BOS onset, with the steepest decline typically seen in the first 6 months (12% decline; p < 0.0001). Bilateral lung transplant recipients had significantly higher FEV(1)%pred at BOS diagnosis (71 vs. 47%; p < 0.0001) and at 24 months after BOS onset (58 vs. 41%; p = 0.0001). Female gender and pretransplant diagnosis of idiopathic pulmonary fibrosis were associated with a steeper decline in FEV(1)%pred in the first 6 months after BOS diagnosis (p = 0.02 and 0.04, respectively). A fall in FEV(1) greater than 20% in the 6 months preceding BOS (termed "rapid onset") was associated with shorter time to BOS onset (p = 0.01), lower FEV(1)%pred at BOS onset (p < 0.0001), steeper decline in the first 6 months (p = 0.03), and lower FEV(1)%pred at 2 years after onset (p = 0.0002). CONCLUSIONS: Rapid onset of BOS, female gender, pretransplant diagnosis of idiopathic pulmonary fibrosis, and single-lung transplantation are associated with worse pulmonary function after BOS onset.
RATIONALE: Bronchiolitis obliterans syndrome (BOS), defined by loss of lung function, develops in the majority of lung transplant recipients. However, there is a paucity of information on the subsequent course of lung function in these patients. OBJECTIVES: To characterize the course of FEV(1) over time after development of BOS and to determine the predictors that influence the rate of functional decline of FEV(1). METHODS: FEV(1)% predicted (FEV(1)%pred) trajectories were studied in 111 lung transplant recipients with BOS by multivariate, linear, mixed-effects statistical models. MEASUREMENTS AND MAIN RESULTS: FEV(1)%pred varied over time after BOS onset, with the steepest decline typically seen in the first 6 months (12% decline; p < 0.0001). Bilateral lung transplant recipients had significantly higher FEV(1)%pred at BOS diagnosis (71 vs. 47%; p < 0.0001) and at 24 months after BOS onset (58 vs. 41%; p = 0.0001). Female gender and pretransplant diagnosis of idiopathic pulmonary fibrosis were associated with a steeper decline in FEV(1)%pred in the first 6 months after BOS diagnosis (p = 0.02 and 0.04, respectively). A fall in FEV(1) greater than 20% in the 6 months preceding BOS (termed "rapid onset") was associated with shorter time to BOS onset (p = 0.01), lower FEV(1)%pred at BOS onset (p < 0.0001), steeper decline in the first 6 months (p = 0.03), and lower FEV(1)%pred at 2 years after onset (p = 0.0002). CONCLUSIONS: Rapid onset of BOS, female gender, pretransplant diagnosis of idiopathic pulmonary fibrosis, and single-lung transplantation are associated with worse pulmonary function after BOS onset.
Authors: Elbert P Trulock; Leah B Edwards; David O Taylor; Mark M Boucek; Paul J Mohacsi; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2003-06 Impact factor: 10.247
Authors: Marshall I Hertz; David O Taylor; Elbert P Trulock; Mark M Boucek; Paul J Mohacsi; Leah B Edwards; Berkeley M Keck Journal: J Heart Lung Transplant Date: 2002-09 Impact factor: 10.247
Authors: J S Sager; R M Kotloff; V N Ahya; D Hadjiliadis; R Simcox; N P Blumenthal; J Mendez; W B Bilker; A Pochettino; J D Christie Journal: Am J Transplant Date: 2006-07-06 Impact factor: 8.086
Authors: H U Meier-Kriesche; A O Ojo; S F Leavey; J A Hanson; A B Leichtman; J C Magee; D M Cibrik; B Kaplan Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: Christopher H Jackson; Linda D Sharples; Keith McNeil; Susan Stewart; John Wallwork Journal: J Heart Lung Transplant Date: 2002-06 Impact factor: 10.247
Authors: Esther Okeke Belmaati; Martin Iversen; Klaus F Kofoed; Michael B Nielsen; Jann Mortensen Journal: Interact Cardiovasc Thorac Surg Date: 2012-03-09
Authors: C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Natalie M Walker; Linda N Badri; Anish Wadhwa; Scott Wettlaufer; Marc Peters-Golden; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Jamie L Todd; Megan L Neely; C A Finlen Copeland; Courtney W Frankel; John M Reynolds; Scott M Palmer Journal: J Heart Lung Transplant Date: 2018-10-31 Impact factor: 10.247
Authors: Jason M Gauthier; Daniel Ruiz-Pérez; Wenjun Li; Ramsey R Hachem; Varun Puri; Andrew E Gelman; Daniel Kreisel Journal: Transplantation Date: 2018-09 Impact factor: 4.939
Authors: Matthew T Hardison; F Shawn Galin; Christopher E Calderon; Uros V Djekic; Suzanne B Parker; Keith M Wille; Patricia L Jackson; Robert A Oster; K Randall Young; J Edwin Blalock; Amit Gaggar Journal: J Immunol Date: 2009-04-01 Impact factor: 5.422